Ibandroninezuur Teva

Active Ingredient:: Ibandronic Acid
Origin:: EU

Ibandroninezuur Teva (Ibandronic Acid)

Q: What is Ibandroninezuur Teva used for?

Ibandroninezuur Teva contains ibandronic acid, a bisphosphonate indicated for the treatment of osteoporosis in postmenopausal women and men, and for the prevention of osteoporotic fractures in patients at high risk of fragility fractures.

Q: How does ibandronic acid work?

Ibandronic acid binds to hydroxyapatite at active bone remodeling sites. When osteoclasts attach, the drug is internalized, disrupting the mevalonate pathway, leading to osteoclast apoptosis and reduced bone resorption, which increases bone mineral density and lowers fracture risk.

Q: What is the usual dose of Ibandroninezuur Teva?

The specific dose and infusion schedule are determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and treatment goals. Dosing information is provided in the product’s prescribing information.

Q: Is Ibandroninezuur Teva safe during pregnancy or breastfeeding?

Safety of ibandronic acid in pregnancy and lactation has not been established. It is generally contraindicated in pregnant or nursing women unless the potential benefit justifies the potential risk to the fetus or infant.

Q: How do I order Ibandroninezuur Teva from GNH India?

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Q: How does Ibandroninezuur Teva compare with other bisphosphonates?

Ibandroninezuur Teva is administered intravenously once yearly or once every three months, offering less frequent dosing than oral bisphosphonates such as alendronate. Compared with zoledronic acid, another IV bisphosphonate, ibandronate has a similar efficacy profile but may have a slightly lower incidence of acute phase reactions.

Q: What are the storage and handling requirements for Ibandroninezuur Teva?

The product should be stored at ambient temperature, below 25 °C, in its original packaging. Protect it from moisture, direct sunlight and extreme temperatures to maintain stability until administration.

Q: How is Ibandroninezuur Teva administered?

Ibandroninezuur Teva is given as an intravenous infusion by a qualified healthcare professional. The infusion is typically administered over 15–30 minutes, followed by observation for any acute reactions before the patient is discharged.

Q: What are the most serious risks associated with Ibandroninezuur Teva?

Serious risks include osteonecrosis of the jaw, atypical femur fractures, severe renal impairment or acute kidney injury, and anaphylactic or severe hypersensitivity reactions. Patients should be monitored for these events, and treatment should be discontinued if they occur.

Q: Who should not use Ibandroninezuur Teva?

Ibandroninezuur Teva is contraindicated in patients with known hypersensitivity to ibandronate or other bisphosphonates, in those with severe renal impairment (eGFR <30 mL/min), and in individuals with existing osteonecrosis of the jaw. Caution is also advised for patients with low serum calcium levels.

Ibandronic acid, the active ingredient in Ibandroninezuur Teva, is a bisphosphonate presented as an intravenous solution for intravenous use. It is indicated for the treatment of osteoporosis in postmenopausal women and men, and for the prevention of osteoporotic fractures.

GNH India supplies Ibandroninezuur Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution, with appropriate temperature control and traceability for import requirements.

Manufacturer / TM Owner

Teva Nederland B.V.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ibandronic acid is used in the management of bone‑resorptive disorders, primarily osteoporosis.
Postmenopausal osteoporosis: administered intravenously, it reduces the incidence of vertebral and non‑vertebral fractures by improving bone strength.
Osteoporosis in men: enhances bone mineral density and decreases the likelihood of fragility fractures in male patients with low bone mass.
Prevention of osteoporotic fractures: offers sustained anti‑resorptive effect to lower the risk of future fractures in patients identified as high risk.

How It Works

Ibandronic acid binds selectively to hydroxyapatite crystals at sites of active bone remodeling. When osteoclasts attach to the drug‑coated bone surface, the compound is internalized, disrupting the mevalonate pathway and inducing osteoclast apoptosis. This inhibition of osteoclast‑mediated bone resorption leads to a net increase in bone mineral density and reduced fracture risk. The high affinity for bone mineral ensures prolonged retention, allowing infrequent dosing intervals while maintaining therapeutic effect.

Side Effects

Ibandronic acid may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

Flu‑like acute phase reaction: fever, chills, muscle aches occurring within 24–48 hours after infusion.
Nausea or vomiting: mild gastrointestinal upset that may resolve spontaneously.
Headache: transient headache reported during the first few days post‑dose.
Transient hypocalcemia: temporary drop in serum calcium levels, often asymptomatic.

Serious or Rare Side Effects

Osteonecrosis of the jaw: exposed necrotic bone in the maxillofacial region, potentially requiring surgical intervention.
Atypical femur fracture: low‑energy subtrochanteric or diaphyseal fracture associated with prolonged bisphosphonate use.
Severe renal impairment or acute kidney injury: rapid rise in serum creatinine necessitating discontinuation.
Anaphylactic or severe hypersensitivity reaction: rash, bronchospasm, hypotension requiring emergency treatment.

Precautions & Warnings

Before initiating therapy with Ibandronic acid, several safety considerations should be observed.

Renal function assessment: evaluate creatinine clearance; avoid in severe renal impairment (eGFR <30 mL/min).
Calcium and vitamin D status: ensure adequate supplementation to prevent hypocalcemia.
Contraindication in hypersensitivity: do not administer to patients with known allergy to ibandronate or other bisphosphonates.
Monitor for acute phase reactions: observe patients for fever or flu‑like symptoms after infusion.
Avoid concurrent nephrotoxic agents: limit use of NSAIDs, aminoglycosides, or contrast media around the infusion.
Store at ambient temperature: keep in original packaging, protect from moisture and light.

Avoid Interactions

Ibandronic acid can interact with other medicines, influencing its safety or effectiveness.

Major Interactions (Avoid)

Concomitant use of other bisphosphonates: additive bone suppression increases risk of oversuppression and jaw osteonecrosis.
Simultaneous IV administration of nephrotoxic drugs (e.g., aminoglycosides, high‑dose NSAIDs): may exacerbate renal toxicity.
High‑dose calcium infusions given within 30 minutes: reduces ibandronate binding to bone and diminishes efficacy.

Moderate Interactions (Monitor Closely)

Oral calcium or antacids taken within 30 minutes of infusion: may lower absorption; separate administration times.
Warfarin or other anticoagulants: monitor INR as bisphosphonates may affect coagulation parameters.
Corticosteroids or hormone‑replacement therapy: may modify bone turnover; assess bone density periodically.

Frequently Asked Questions

Ibandroninezuur Teva contains ibandronic acid, a bisphosphonate indicated for the treatment of osteoporosis in postmenopausal women and men, and for the prevention of osteoporotic fractures in patients at high risk of fragility fractures.

Ibandronic acid binds to hydroxyapatite at active bone remodeling sites. When osteoclasts attach, the drug is internalized, disrupting the mevalonate pathway, leading to osteoclast apoptosis and reduced bone resorption, which increases bone mineral density and lowers fracture risk.

The specific dose and infusion schedule are determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and treatment goals. Dosing information is provided in the product’s prescribing information.

Safety of ibandronic acid in pregnancy and lactation has not been established. It is generally contraindicated in pregnant or nursing women unless the potential benefit justifies the potential risk to the fetus or infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Ibandroninezuur Teva is administered intravenously once yearly or once every three months, offering less frequent dosing than oral bisphosphonates such as alendronate. Compared with zoledronic acid, another IV bisphosphonate, ibandronate has a similar efficacy profile but may have a slightly lower incidence of acute phase reactions.

The product should be stored at ambient temperature, below 25 °C, in its original packaging. Protect it from moisture, direct sunlight and extreme temperatures to maintain stability until administration.

Ibandroninezuur Teva is given as an intravenous infusion by a qualified healthcare professional. The infusion is typically administered over 15–30 minutes, followed by observation for any acute reactions before the patient is discharged.

Serious risks include osteonecrosis of the jaw, atypical femur fractures, severe renal impairment or acute kidney injury, and anaphylactic or severe hypersensitivity reactions. Patients should be monitored for these events, and treatment should be discontinued if they occur.

Ibandroninezuur Teva is contraindicated in patients with known hypersensitivity to ibandronate or other bisphosphonates, in those with severe renal impairment (eGFR <30 mL/min), and in individuals with existing osteonecrosis of the jaw. Caution is also advised for patients with low serum calcium levels.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 31 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.